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1 PATIENT PRESENTATION
Weshow a computed tomography (CT) scan of a 53-year-oldmalewith
stage IVmucinous (ALK)-rearranged lung adenocarcinoma responding
to Lorlatinib (ALK-inhibitor, targeted therapy) (Figure 1). He presented
to the emergency department with a productive cough, developing
acute hypoxic respiratory failure requiring 10 L supplemental oxygen,
and was subsequently admitted to the hospital for 14 days. His CT
F IGURE 1 Chest CT for patient on Lorlatinib. Chronic large right
side pleural effusion, right sided chest mass, and diffuse ground glass
opacities concerning for drug induced pneumonitis versus Covid-19
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scan was remarkable for improving right perihilar mass, recurrent, and
stable large right-sided pleural effusion, and diffuse bilateral ground
glass opacities concerning for COVID-19 versus drug-induced pneu-
monitis. Laboratory tests were remarkable for lymphopenia, ferritin of
550 ng/mL, C-reactive protein (CRP) 8.2mg/dL, and a D-dimer 3.0mcg
FEU/mL. Initial influenza and respiratory viral panels were negative.
COVID-19 PCR testing took 10 days to result, subsequently return-
ing positive. The patient completed treatment for possible community-
acquired pneumonia in the hospital and had received 1 dose of methyl-
prednisolone IV for possible Lorlatinib-induced pneumonitis. At time
of hospital discharge, he dramatically improved and was discharged on
room air, without newmedications, with plans to restart Lorlatinib.
This case demonstrates the challenge of differentiating between
tyrosine-kinase inhibitor-induced pneumonitis and COVID-19, further
illustrating the need for rapid emergent COVID-19 testing in high risk
patients. Currently COVID-19 polymerase chain reaction (PCR) rep-
resents the only way to differentiate drug-induced pneumonitis from
COVID-19. It is imperative that emergency physicians recognize the
adverse effects of cancer immunotherapy and be in immediate com-
munication with the treating oncologist, because early intervention is
crucial in the treatment of drug-induced pneumonitis.
How to cite this article: Pettit N, Al-Hader A.Manwith
productive cough. JACEP Open. 2020;1-1.
https://doi.org/10.1002/emp2.12122
JACEPOpen 2020;1. wileyonlinelibrary.com/journal/emp2 1
